



OPEN ACCESS

EDITED BY

Kosuke Nishi,
Ehime University, Japan

REVIEWED BY

Coen Govers,
Wageningen University and Research,
Netherlands
Chi-Heng Wu,
Dren Bio, Inc., United States

*CORRESPONDENCE

Linette E. M. Willemsen
✉ l.e.m.willemsen@uu.nl

RECEIVED 04 September 2024

ACCEPTED 30 January 2025

PUBLISHED 19 February 2025

CITATION

Zuurveld M, de Kleer JWM, Berends AJ,
Kooy MM, Van Ark I, Leusink-Muis T,
Kettelarij N, Folkerts G, Garssen J, van't
Land B and Willemsen LEM (2025) HMOS 2'FL
and 3FL prevent house dust mite induced
proinflammatory cytokine release *in vitro* and
decrease specific IgE production in a murine
allergic asthma model.
Front. Nutr. 12:1491430.
doi: 10.3389/fnut.2025.1491430

COPYRIGHT

© 2025 Zuurveld, de Kleer, Berends, Kooy,
Van Ark, Leusink-Muis, Kettelarij, Folkerts,
Garssen, van't Land and Willemsen. This is an
open-access article distributed under the
terms of the [Creative Commons Attribution
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that the
original publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or reproduction
is permitted which does not comply with
these terms.

HMOS 2'FL and 3FL prevent house dust mite induced proinflammatory cytokine release *in vitro* and decrease specific IgE production in a murine allergic asthma model

Marit Zuurveld¹, Janna W. M. de Kleer¹, Alinda J. Berends¹,
Manou M. Kooy¹, Ingrid Van Ark¹, Thea Leusink-Muis¹,
Nienke Kettelarij², Gert Folkerts¹, Johan Garssen^{1,2},
Belinda van't Land^{2,3} and Linette E. M. Willemsen^{1*}

¹Division of Pharmacology, Faculty of Science, Utrecht Institute for Pharmaceutical Science, Utrecht University, Utrecht, Netherlands, ²Danone Research and Innovation, Utrecht, Netherlands, ³Center for Translational Immunology, University Medical Centre Utrecht, Utrecht, Netherlands

Introduction: Allergic asthma is characterized by sensitization to airborne allergens like house dust mite (HDM). Human milk oligosaccharides (HMOS) are linked to improved immune maturation and potentially alleviate allergy development.

Methods: A human *in vitro* model for crosstalk between bronchial epithelial cells (BECs), monocyte-derived DCs (moDCs) and T cells, during HDM exposure, was established. The immunomodulatory effects of the HMOS 2'-fucosyllactose (2'FL) and 3-fucosyllactose (3FL) were investigated in this *in vitro* model and subsequently in a house dust mite-induced allergic asthma murine model.

Results: HDM exposure during BEC-DC coculture enhanced type 2 instructing TSLP, while reducing regulatory TGF β secretion. Coculture of HDM-primed DCs with T cells enhanced IL4 secretion. 2'FL or 3FL preincubation prevented HDM-induced TSLP and IL8 release from BEC-DC. HDM-allergic mice receiving a 1% 2'FL or 0.5% 3FL supplemented diet both had lower serum levels of HDM-specific IgE compared to mice fed control diet. In conclusion, a human *in vitro* coculture model for HDM-induced BEC-DC activation and subsequent type 2 T cell response was established. 2'FL or 3FL preincubation of BEC-DC prevented HDM-induced activation and modified downstream T cell responses *in vitro*. Both HMOS reduced HDM-specific IgE in a murine model for HDM allergic asthma, but did not protect against airway inflammation.

Conclusion: Here, we describe an *in vitro* human airway mucosal HDM sensitization model as relevant tool to reduce use of animals in studies aiming to prevent HDM allergic asthma. Both *in vitro* as well as *in vivo*, HMOS were found to drive away from a type 2 immune signature, paving the way to further investigate the potential allergy preventive effects of fucosylated HMOS.

KEYWORDS

advanced *in vitro* models, allergic asthma, human milk oligosaccharides, mucosal inflammation, allergy prevention

1 Introduction

Allergic asthma is common in Westernized countries, with as many as 1 in 10 children and 1 in 12 adults affected (1). A total of 300 million people worldwide is affected by the disease. Allergic asthma is characterized by sensitization to airborne allergens, which leads to T helper 2 cell (Th2) mediated airway inflammation and asthma symptoms (2). The most common allergens in allergic asthma are derived from house dust mite (HDM), animal dander, cockroaches and fungi (3). Sensitization to allergens mostly occurs in children within the first year of life, often accompanied by atopic eczema (1). These children are generally more susceptible to develop food allergy, as well as allergic rhinitis and allergic asthma later in life (4). There is no curative treatment available for allergic asthma and medication generally consists of a combination of inhaled corticosteroids and short- or long-acting β 2-adrenergic agonists. Allergic asthma might lead to chronic inflammation of the respiratory tract in which bronchial epithelial cells (BEC) and innate and adaptive immune cell activation contribute to type 2 inflammation, tissue remodeling and bronchial hyperreactivity (BHR) (1). Symptoms include shortness of breath, wheezing, coughing, and chest tightness (5).

Allergic sensitization has been linked to decreased epithelial barrier function. Disruption of this epithelial barrier, can lead to increased sensitization as allergens can enter the lamina propria more easily, leading to increased exposure to immune cells (6, 7). Thus, airway epithelial integrity is crucial in preventing sensitization and serves as a first line of defense against unwanted intruders. Besides being a physical barrier, the epithelium expresses pattern recognition receptors such as protease-activated receptors, toll-like receptors (TLR), and C-type lectin receptors, which are involved in allergen binding. Furthermore, several allergens found in HDM, including Der p 1, have protease activity (8) disrupting epithelial tight junctions (9, 10). Binding of allergens to epithelial receptors leads to activation of these epithelial cells and the release of alarmins, such as thymic stromal lymphopoietin (TSLP), interleukin (IL)25 and IL33 (11). These alarmins act together with chemokines to activate and/or recruit DCs, innate lymphoid cells type 2 (ILC2) or eosinophils, which promote the inflammatory response (1, 8, 12).

Uptake of allergens by antigen-presenting cells (APCs) occurs through sampling of the airway lumen by dendritic cells (DCs) or through allergens crossing the bronchial epithelium into the underlying lamina propria. Following uptake of the allergen and instruction via epithelial derived mediators, DCs travel to the mediastinal lymph nodes to present the captured allergen within their MHC class II receptor (MHCII) to the T cell receptor (TCR) on naïve Th cells which may lead to differentiation into Th2 cells in the case of allergic sensitization (12). Allergen-specific Th2 cells activate allergen-specific B cells, which leads to class switching of the B cells towards immunoglobulin E (IgE) producing plasma cells. Secreted allergen-specific IgE binds to the high affinity receptor Fc ϵ RI present on mast cells. At a second encounter with the allergen, allergen-specific IgE on the surface of mast cells crosslinks by binding to the allergen, leading to mast cell degranulation (13, 14). Degranulation involves the release of pro-inflammatory mediators, which induce vasodilation, bronchoconstriction, and eosinophilic airway inflammation which becomes chronic when being uncontrolled (15).

As treatment of allergic asthma currently mainly consists of symptom suppression, preventing the development of allergic asthma

has acquired scientific interest. The World Health Organization recommends exclusive breastfeeding for the first 6 months of life as it has overwhelming benefits for both mother and infant (16), including potential protection from allergic asthma development (17). Human milk oligosaccharides (HMOS) are the third largest solid component of breastmilk after lipids and lactose, present in concentrations of up to 25 g/L in colostrum and 5–15 g/L in mature milk (18–20) and are thought to benefit immune maturation and protect against infections (14, 21). HMOS are resistant to low gastric pH and cannot be digested by humans. However, they are substrates for bacterial fermentation in the large intestine (22, 23). In addition, a small amount of ingested HMOS can be traced back in the blood and urine of the suckling infant (24–26). HMOS directly bind to pathogens, promote growth of beneficial bacteria, can be used to produce bioactive metabolites like short chain fatty acids (SCFA) and act directly on receptors from epithelial cells and immune cells (14). Therefore, differential effects from specific HMOS can be postulated in preventing the development of allergic asthma.

All mammalian milk contains oligosaccharides, but this is generally found in a concentration 10–100 fold lower than in humans (27). Over 150 different HMOS structures have been identified, and are present in human milk (19, 28). Variety in the produced HMOS substantially differs per individual. Factors such as period of lactation or polymorphism of the Lewis and Secretor genes can influence the variety and quantity of HMOS in breastmilk (19). Neutral HMOS account for 75% of the total HMOS in human milk. All women can secrete the neutral fucosylated 3-fucosyllactose (3FL), independent of the expression of the Secretor or Lewis gene (29, 30). In women who express an active form of the Secretor gene (approximately 70% of women), the most abundant HMOS is 2'-fucosyllactose (2'FL). Although 2'FL and 3FL are structurally alike, affinities for different receptors have been described (14) and although this has not been studied in depth, we hypothesize that their effects on the neonatal immune development may be distinguishable.

Currently it is unknown whether these HMOS may protect against allergic sensitization. Therefore, the aim of this study was to develop a human *in vitro* bronchial epithelial mucosal immune model to study the crosstalk between BEC, DCs and T cells after exposure to HDM, based on the models previously published for the intestinal mucosa (31–33). Furthermore, the potential immunomodulatory effects of the commonly expressed HMOS 2'FL and 3FL were investigated in this *in vitro* model. Additionally, an *in vivo* murine HDM-induced acute allergic asthma model was used to study the immunomodulatory effects of a dietary intervention with 2'FL and 3FL.

2 Materials and methods

2.1 *In vitro* culture and isolation of BEC, moDC, and T cells

2.1.1 Calu-3 cell culture

Human lung adenocarcinoma Calu-3 cells (American Type Culture Collection, USA, passage 29–32) were used as a model for BEC. Cells were grown in minimal essential medium (MEM) (Gibco, USA) supplemented with 10% fetal bovine serum (FBS, Gibco), 1% penicillin, 1% streptomycin, 1% non-essential amino acids (Gibco), and 1% sodium pyruvate (Gibco) in a 75 cm² culture flask (Greiner, Germany) until approximately 75% confluency was reached. After

trypsinization, cells were seeded on inserts (3.0 μm pores) of a 24-wells transwell plate (Corning Incorporated, USA) in 200 μl medium. 500 μl medium was added to the basolateral compartment. The cells were incubated in 5% CO_2 at 37°C. After 24 h (24 h) all medium was removed and only 300 μl basolateral medium was added to start air-liquid interface (ALI) culture. 200 μl was added to the apical compartment and 500 μl to the basolateral compartment for submerged culture. Medium was refreshed every 3–4 days. Cells were cultured for 2 weeks until 100% confluency, differentiation of the cells was assessed by measuring trans-epithelial electrical resistance (TEER) using the Locsense Artemis (Locsense, The Netherlands) or the Millicell ERS-2 Volt-ohm meter (Merck Millipore, USA).

2.1.2 PBMC isolation

Buffy-coats were obtained from healthy donor blood from the Dutch Blood Bank. Human peripheral blood mononuclear cells (PBMC) were isolated by density gradient centrifugation (1,000 $\times g$, 13 min) using Leucosep tubes (Greiner Bio-One, the Netherlands). The pellet was washed three times with PBS containing 2% FBS. To remove the remaining erythrocytes, lysis buffer was added (8.3 mg NH_4HCl , 1 g KHC_3O , 37.2 mg EDTA in 1 L demi water, sterile filtered) for 5 min. Cells were resuspended in 10 ml RPMI 1640 (Sigma-Aldrich, USA) supplemented with 10% FBS, 1% penicillin and 1% streptomycin. Obtained PBMCs were counted using the Z1 Coulter Particle Counter (Beckman Coulter, The Netherlands).

2.1.3 Monocyte and naïve Th cell isolation

The PBMC suspension was centrifuged (300 $\times g$, 10 min), the supernatant was discarded and the pellet resuspended in isolation buffer (2.5 g BSA, 2 mM EDTA in 500 ml PBS). Monocytes were isolated via negative selection using a QuadroMACS separator, LS columns and Monocyte Isolation kit II or naïve Th cells via a Naïve CD4+ T cell isolation kit (Miltenyi Biotec, Germany) according to manufacturer's instruction. Collected flow through contained the enriched cell fraction and was centrifuged (300 $\times g$, 10 min). Monocyte containing pellets were resuspended in RPMI 1640 supplemented with 10% FBS, 1% penicillin, and 1% streptomycin. Naïve Th cell containing pellets were resuspended in IMDM supplemented with 5% FBS, 1% penicillin, 1% streptomycin, 20 $\mu\text{g}/\text{ml}$ apo-transferrin, and 50 μM β -mercaptoethanol. Cells were counted using the Z1 Coulter Particle Counter (Beckman Coulter). Isolated naïve Th cells were stored in 90% FBS and 10% DMSO in liquid nitrogen until further use.

2.1.4 Monocyte derived dendritic cell culture

Monocytes were cultured in a 6 well plate (Greiner Bio-One) in RPMI 1640 supplemented with 10% FBS, 1% penicillin, and 1% streptomycin. Cytokines were added to a final concentration of 100 ng/ml IL4 and 60 ng/ml GM-CSF (ProSpec Bio, Israel) to induce differentiation into dendritic cells. Half of the medium and cytokines were refreshed every other day. Cells were cultured for 6 days before experimental use. After 6 days, moDCs were counted and diluted to a concentration of 1.5×10^6 cells/ml for use in coculture experiments.

2.2 HDM dose response in BEC

After 14 days of culture in transwell, Calu-3 cells were apically exposed for 72 h to increasing doses of HDM extract (10–250 $\mu\text{g}/\text{ml}$,

Greiner Laboratories, USA). TEER was measured during this exposure period ($t = 0$ h, 1 h, 6 h, 12 h, 24 h, 72 h) and basolateral supernatants were collected after 24 h to measure cytokine secretion.

2.3 Airway epithelial mucosal immune coculture model

2.3.1 Calu-3/moDC coculture

500 μl of moDC suspension (1.0×10^6 cells/ml) was added to the wells of a 24-wells plate (Greiner Bio-One), if appropriate inserts containing confluent ALI-cultured Calu-3 cells were added. MoDCs were (basolateral) exposed to 0,01% or 0,05% 2'FL or 3FL (Carbosynth, UK) and incubated for 24 h at 37°C, 5% CO_2 . Next, epithelial cells or moDC were apically exposed to 10 $\mu\text{g}/\text{ml}$ HDM (in 200 μl) and incubated for 24 h at 37°C, 5% CO_2 . Afterwards, basolateral supernatant was collected and stored at -20°C for cytokine measurement, moDCs were collected for analysis by flow cytometry or subsequent coculture with naïve Th cells.

2.3.2 MoDC/Naïve Th cell coculture

5×10^4 MoDCs were collected for subsequent coculture with naïve Th cells and were transferred to a 48-well culture plate (Greiner Bio-One) in 100 μl coculture medium (IMDM supplemented with 5% FBS, 1% penicillin, 1% streptomycin, 20 $\mu\text{g}/\text{ml}$ apo-transferrin, and 50 μM β -mercaptoethanol). Isolated naïve Th cells were thawed and diluted to a concentration of 1.25×10^6 cells/ml in coculture medium. 400 μl allogenic naïve Th cell suspension was added to the moDC suspension in the wells (1:10 DC:T cell ratio). Activation of naïve Th cells was aided by adding 5 ng/ml IL2 (ProSpec Bio) and 150 ng/ml anti-CD3 (BD Biosciences, USA) to the culture. The coculture was incubated for 5 days without medium refreshments. Cells were collected for flow cytometric analysis and supernatants were stored at -20°C for cytokine analysis.

2.4 *In vivo* house dust mite induced acute allergic mouse model

2.4.1 Diet preparation

Experimental diets (produced by ssniff-Spezialdiäten GmbH, Germany) were based on an AING93 diet. This diet was adapted by addition of methionine and cysteine, and soy protein was used instead of casein. Furthermore, diets were supplemented with or without 0,5% or 1% 2'FL or 3FL (Jenneweine GmbH, Germany). Supplementation of 2'FL and 3FL was isocaloric compensated with cellulose. Animals had ad libitum access to food and water, which were fully refreshed weekly.

2.4.2 Animals

Six to seven week-old male BALB/cAnNCrl mice (Charles River, Germany) arrived at the animal facility of Utrecht University and were housed in individual ventilated cages with a 12 h/12 h light/dark cycle, controlled relative humidity (50–55%) and temperature ($21 \pm 2^\circ\text{C}$). Mice were randomly allocated to the experimental groups and housed with 3 animals per cage. Cage enrichment consisted of woodchipped bedding, wood curls (as nesting material) and a plastic shelter. This study was conducted in accordance with institutional guidelines for the care and use of laboratory animals of the Utrecht University, and all animal

procedures were approved by the local Animal Welfare Body under an Ethical license provided by the national competent authority (Centrale Commissie Dierproeven, CCD), securing full compliance the European Directive 2010/63/EU for the use of animals for scientific purposes.

2.4.3 Animal procedures

A schematic overview of the experimental setup is shown in [Figure 1A](#). After arrival mice immediately received the experimental diets. 14 days later, the mice were intranasally sensitized with 1 µg HDM (Greer Laboratories) in 40 µl PBS under isoflurane anesthesia. Mice were intranasally challenged on days 21–25 with 10 µg HDM in 40 µl PBS. 72 h after the final challenge, airway hyperresponsiveness was measured. Subsequently, mice were sacrificed by intraperitoneal overdose of pentobarbital (Nembutal™, Ceva Santé Animale, The Netherlands) and samples were collected for further analysis.

2.4.4 Serum analysis

Mice were sacrificed and blood was collected via eyeball extraction in a Minicollect serum tube (Greiner Bio-One B.V., Netherlands). Collected blood was kept at room temperature for at least 30 min prior to centrifugation for 10 min at 14,000 rpm. Serum was collected and stored at –20°C for antibody measurement.

2.4.5 Bronchoalveolar lavage

After sacrificing, lungs were lavaged four times with 1 ml saline solution (0.9% NaCl, 37°C). Bronchoalveolar lavage (BAL) fluid was centrifuged (400 × g, 5 min) and the BAL cell-containing pellets were pooled. Total cell count was determined using a Bürker-Türk chamber (magnification 100x). Cytospin preparations were made and stained with Diff-Quick (Merz & Dade A.G., Switzerland) for differential BAL cell count. Cell counts were scored with light microscopy.

2.4.6 Preparation of lung homogenates

Collected lung tissue was homogenized using 1% Triton X100 (Sigma-Aldrich) in PBS containing protease inhibitor (Complete Mini, Roche Diagnostics) with a Precellys Tissue Homogenizer and Precellys homogenizer tubes (Bertin, Rockville, MD, USA). Homogenates were centrifuged at for 10 min at 14000 rpm. Supernatant was collected and stored at –20°C for cytokine analysis.

2.4.7 Preparation of lung single cell suspension

Lung tissue was collected after sacrifice and enzymatic digested using a buffer containing DNase I and Collagenase A (Roche Diagnostics, Switzerland). FBS was added to stop the digestion after 30 min. The lung tissue was passed through a 70 µm filter to obtain single cell suspensions. Cell suspensions were incubated for 4 min on ice in red blood cell lysis buffer (4.14 g NH₄Cl, 0.5 g KHCO₃, 18.6 mg NA₂EDTA in 500 ml demi water, sterile filtered, pH 7.4). Lysis was stopped by adding FBS. Lung cells were washed with RPMI 1640 (Lonza, USA). After counting the cells with Z1 Coulter Particle Counter (Beckman Coulter Life Sciences), cells were stained for analysis by flow cytometry.

2.5 ELISAs

In vitro cytokine levels were determined in collected supernatants. IL4, IL8, IL10, IL13, IFN γ , TGF β , TSLP (Invitrogen, USA), IL25 and

IL33 (R&D systems, Minneapolis, MN, USA) were determined according to manufacturer's protocol. Optical density was measured at 450 nm.

To measure HDM-specific IgE levels in serum from mice, high binding 96 well plates (Corning Costar) were coated with HDM (50 µg/ml) and incubated overnight at 4°C. After blocking with 1% BSA in PBS, plates were washed and diluted serum samples were added to incubate for 2 h. Plates were washed again and 1 µg/ml biotin anti-mouse IgE (BD Biosciences) was added for 1.5 h. Plates were incubated with streptavidin-HRP for 30 min, followed by addition of a substrate solution. Washing steps were performed in between. Reaction was stopped by addition of 2 M H₂SO₄ and absorbance was measured at 450 nm.

Concentrations of IL13, IFN γ and IL10 (Invitrogen) in lung homogenates were measured according to the manufacturer's instructions. Levels of cytokines were calculated per mg of homogenized lung tissue.

2.6 Flow cytometry staining


Cells were stained with Fixable Viability Dye eFluor780 for 30 min. Aspecific binding was blocked using human FC block (BD Biosciences) in PBS for *in vitro* samples and antiCD16/CD32 blocking buffer for murine samples. Subsequently samples were stained for 30 min at 4°C using titrated amounts of antibodies. To allow intranuclear staining of transcription factors, cells were fixated and permeabilized using FoxP3/Transcription Factor staining buffer set (eBioscience, USA) following the manufacturer's instructions. For intracellular staining, cells were fixated and permeabilized with Intracellular Fixation & Permeabilization Buffer Set (eBioscience) according to manufacturer's protocol. FACS Canto II (BD Biosciences) was used to measure stained samples and obtained data was analysed using Flowlogic Software (Invai Technologies, Australia).

Titrated amounts of the following antibodies were used to stain *in vitro* samples: CD11c-PerCP (3.9), HLA-DR-PE (LN3), CD80-FITC (2D10.4), CD86-PE/Cy7 (IT2.2) (All from eBioscience, USA), CD4-PerCP (OKTO4, eBioscience), CXCR3-Alexa Fluor 488 (1C6/CXCR3, BD Biosciences), CRTH2-APC (BM16, BD Biosciences), FoxP3-eFluor 660 (PCH101, Invitrogen), CD25-Alexa Fluor 488 (BC96, eBioscience), and IL13-PE (85BRD, eBioscience), and IFN γ -Amcyan (4S.B3, Biolegend). The gating strategy using representative samples is shown in [Supplementary Figure 1](#).

Titrated amounts of the following antibodies were used to stain murine samples: CD4-BV510 (RM4-5, Biolegend), CD69-PE-Cy7 (H1.2F3, eBioscience), CXCR3-PE (CXCR3-173, eBioscience), T1ST2-FITC (DJ8, MD Bioproducts, USA), FoxP3-FITC (FJK-16 s, Invitrogen), CD127-PE/Vio770 (A7R 34, Miltenyi Biotec) and CD25-PerCP/Cy5.5 (PC61.5, Invitrogen).


2.7 Statistical analysis

Statistical analyses were performed using Graphpad Prism (Version 10.4.1) software. TEER data was analyzed by Two-Way ANOVA followed by Bonferroni multiple comparisons test. After exposure to increasing HDM concentrations, cytokine levels were



analyzed by One-Way ANOVA followed by Dunnett's multiple comparison test comparing all HDM concentration to the control condition. Control and HDM conditions (in presence or absence of BEC) were analyzed by paired t-test. When data fit the normal distribution and had an equal variability of differences between groups, effects of HMOS preincubations were analyzed by One-Way ANOVA followed by Dunnett's multiple comparisons test comparing all conditions to the HDM-exposed condition. If these criteria were not met the following steps were taken in this order, data was transformed, a Geisser–Greenhouse correction was performed or a Friedman-test

with Dunn's multiple comparisons test was performed. Murine data was comparing Sham and HDM groups, and HDM group with the intervention groups. When data fit a normal distribution and had an equal variability of differences, Sham and HDM groups are analyzed by unpaired t-test, the intervention groups were compared to the HDM group by One-Way ANOVA followed by a Dunnett's multiple comparisons test. When these criteria were not met, data was transformed, a Mann-Whitney test or Kruskal-Wallis test with Dunn's multiple comparisons test was performed. p < 0.05 is considered statistically significant, data is represented as mean ± SEM of 4–6



independent *in vitro* repeats using biologically different donors, or in case of *in vivo* studies using 6–12 animals per group.

3 Results

3.1 HDM exposure activates ALI cultured BEC and reduces barrier resistance

The initial step to develop an *in vitro* airway epithelial mucosal immune model, consisted of a comparison between ALI and submerged cultured Calu-3 cells. During a culture period of 14 days after seeding, development of barrier resistance was measured by means of TEER. Although a significant difference was found after 10 and 14 days of culture, Calu-3 cells developed proper barrier resistance in the ALI culture (Figure 2A). Therefore all experiments using Calu-3 cells were performed in ALI culture. Next, a dose–response (10–250 $\mu\text{g}/\text{ml}$) HDM was added for 72 h. 10 $\mu\text{g}/\text{ml}$ and 100 $\mu\text{g}/\text{ml}$ HDM significantly decreased barrier resistance as measured already 1 h after exposure (Figure 2B), and a decreasing trend ($p = 0.0503$) was observed using 25 $\mu\text{g}/\text{ml}$ HDM. Secreted cytokines were measured in basolateral supernatants collected 24 h after the start of HDM exposure. IL33 secretion was enhanced using 10 $\mu\text{g}/\text{ml}$ HDM exposure (Figure 2C). Both 10 $\mu\text{g}/\text{ml}$ ($p = 0.0847$) and 50 $\mu\text{g}/\text{ml}$ ($p = 0.0855$) HDM exposure tended to increase IL25 levels, while 250 $\mu\text{g}/\text{ml}$ HDM significantly decreased the release of IL25 (Figure 2D). TSLP secretion was significantly increased using 25 $\mu\text{g}/\text{ml}$ HDM exposure (Figure 2E), whereas none of the HDM concentrations


significantly enhanced IL8 secretion (Figure 2F). Based on these results, a dose of 10 $\mu\text{g}/\text{ml}$ HDM was chosen to be used for further *in vitro* experiments.

The TEER upon HDM exposure was automatically measured by the Locsense Artemis. In subsequent experiments this decrease was not observed, possibly due to manual measurements performed by a Millicell ERS-2 Volt-ohm meter.

3.2 Exposing BEC-DC to HDM induces a Th2 profile during coculture with naive Th cells

BECs cocultured with moDCs (BEC-DC) or moDCs alone were exposed for 24 h to HDM (Figure 3A). moDC exposure to HDM in absence of BECs was found to increase IL33 and TGF β secretion (Figures 3B,D) and the percentage of CD86 expressing DCs (Figure 3G), while the secretion of IL8 tended to be reduced ($p = 0.0633$, Figure 3E). By contrast, when BEC were exposed to HDM while cocultured with moDC, secretion of TSLP (Figure 3C) and the percentage of CD80 expressing DC (Figure 3F) was enhanced, while secretion of TGF β (Figure 3D) was decreased in supernatants collected after 48 h BEC-DC coculture.

Subsequently, primed moDC were cocultured with allogenic naive Th cells to study the functional character of the HDM-DC or HDM-BEC-DC. Although development of Th subsets was unaffected by any of the conditions (Figures 3H,K,N), HDM-DC reduced the



percentage of IL13 or IFN γ containing T cells (Figures 3I,L). By contrast, HDM-BEC-DC enhanced the release of IL4 (Figure 3J) after coculture with naive CD4 $^{+}$ T cells (HDM-BEC-DC/T), while decreasing the percentage of IFN γ containing Th cells (Figure 3L). Although the secretion of IFN γ , IL10 (Figures 3M,O), IL13, IL5 and IL17 (Supplementary Figures 3A–C) remained unaffected, the ratio of IL4 over IFN γ secretion was significantly increased for HDM-BEC-DC-T cells (Figure 3P), displaying the type 2 shifted immune character of HDM-BEC-DC-T cells. As the exposure to HDM via BEC resulted in a type 2 immune response, a relevant contribution of the BEC to the HDM-induced immune activation was hypothesized. Therefore, the latter model was chosen to explore the effects of specific HMOS.

3.3 Both 2'FL and 3FL reduce HDM mediated BEC-DC activation while consecutive BEC-DC/T cell responses are differentially modulated by these HMOS

The previously displayed Control and HDM conditions were compared to HDM exposed cells preincubated with 2'FL or 3FL. Although basolateral incubation of BEC-DC with 2'FL and 3FL showed only minor immunomodulatory effects on moDCs

(Supplementary Figures 2A–F), no significant effects were observed when HMOS-primed moDCs were cocultured with naive Th cells (Supplementary Figures 2G–Q). Next, BEC-DC were incubated basolateral with 2'FL and 3FL, while BEC were apically exposed to HDM. The BEC-DC were cocultured with naive Th cells (Figure 4A). HDM induced TSLP and IL8 secretion (Figures 4C,E) was prevented when BEC-DC were incubated with 2'FL or 3FL. In addition, the HDM reduced TGF β secretion was prevented by exposing the HDM-BEC-DC to 0,01% 3FL but not 2'FL (Figure 4D). IL33 levels or DC maturation were not significantly affected by either HDM exposure 2'FL or 3FL (Figures 4B,F,G). In these cultures TEER was measured, but HDM did not result in a TEER reduction (data not shown).

When combining BEC-DC with T cells, the 0,01% 3FL incubated HDM-BEC-DC were found to reduce the secretion of IL4 (Figure 4) and IL13 (Supplementary Figure 3) from T cells. In addition, the percentage of Th1 cells, characterized by CXCR3 expression, (Figure 4K) was reduced but the IFN γ expression within the T cells was increased when comparing 0,01% 3FL preincubated HDM-BEC-DC-T cells to HDM-BEC-DC-T cells (Figure 4L). Although the secretion of IL5, IL17 (Supplementary Figures 3A–C) and IFN γ (Figure 4M) was not significantly affected by either 2'FL or 3FL preincubation, the ratio of IL4 over IFN γ was significantly reduced by 0,05% 2'FL as well as 3FL




FIGURE 4

A preclinical murine model for house dust mite induced acute allergic asthma was used to investigate the immunomodulatory effects of dietary HMOS. (A) 6 week old male Balb/cAnNCrl mice were fed a control or HMOS supplemented diet 2 weeks prior to intranasal sensitization with HDM. One week after sensitization, mice were intranasally challenged for 5 consecutive days. 72 h after the final challenge, mice were sacrificed for sample collection. Lungs of sacrificed mice were lavaged to determine the influx of (B) the total number of cells, (C) eosinophils and (D) macrophages into the lungs. (E) HDM-specific IgE levels were determined in serum. The correlation between (F) eosinophil influx into the lungs and HDM-specific IgE in serum as well as (G) macrophage influx into the lungs and HDM-specific IgE in serum is displayed. When data fit a normal distribution and had an equal variability of differences, Sham and HDM groups are analyzed by unpaired t-test, the intervention groups were compared to the HDM group by One-Way ANOVA followed by a Dunnett's multiple comparisons test. When these criteria were not met, data was transformed, a Mann-Whitney test or Kruskal-Wallis test with Dunn's multiple comparisons test was performed $n = 6-12$, mean \pm SEM (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$). Correlations were studied using the Spearman's correlation. Some parts of this figure were created with [BioRender.com](https://www.biorender.com).

incubation of HDM-BEC-DC, indicating a shift in balance away from a type 2 immune response (Figure 4P). Furthermore, HDM exposure did not significantly affect the percentage of Treg cells or secretion of regulatory type IL10 (Figures 4N,O).

3.4 HDM sensitized and challenged mice receiving 1% 2'FL or 0,5% 3FL via diets have lower HDM-specific IgE levels in serum

To support the *in vitro* findings, a murine HDM-induced acute allergic asthma model was performed specifically to study the potential immunomodulatory effects of 2'FL and 3FL (Figure 1A). The influx of inflammatory cells into the lungs was increased in HDM-sensitized mice 72 h after the final challenge (Figure 1B). In

particular, the number of eosinophils (Figure 1C) and macrophages (Figure 1D) was enhanced in HDM sensitized and challenged mice as compared to control. Mice receiving an HMOS supplemented diet had similar levels of cell influx into the lungs. No significant increase in airway hyperresponsiveness was observed in HDM sensitized and allergic mice (Supplementary Figure 4). As hallmark parameter of allergic sensitization, HDM-specific IgE levels were measured in serum. HDM sensitized and challenged mice had increased levels of HDM-specific IgE, which was reduced in mice who had received a 1% 2'FL or 0,5% 3FL diet (Figure 1E). Even though the influx of eosinophils and macrophages was not significantly altered in mice receiving an HMOS supplement diet, the number of both eosinophils and macrophages was positively correlated with the levels of HDM-specific IgE in serum (Figures 1F,G).

3.5 Lower levels of pulmonary IL13 and IFN γ in HDM sensitized and challenged mice receiving 1% 3FL containing diets

Lung tissue from sacrificed mice were analyzed for the ratio of present Th cell subsets and cytokine levels. HDM sensitized and challenged mice had a higher percentage of activated Th2 and Th1 cells present (based on expression of T1ST2 and CXCR3, respectively, as well as CD69, Figures 5A,C,E), however these percentages were not altered in the mice receiving either 2'FL or 3FL in their diets. The percentage of regulatory T cells (Treg) remained the same in all HDM sensitized and challenged mice (Supplementary Figure 4B). However, levels of IL13, IFN γ (Figures 5B,D) and IL10 (Supplementary Figure 4C) were lowered in homogenized lung tissue from mice that had received a 1% 3FL enriched diet as compared to mice receiving a control diet.

4 Discussion

HMOs are the third most abundant solid component of human milk, they may act as prebiotics and are believed to have immunomodulatory properties. This may help to prevent allergic diseases such as type 2 asthma. Therefore, the immunomodulatory properties of two commonly expressed fucosylated HMOs, 2'FL and 3FL, were investigated in an *in vitro* bronchial epithelial HDM induced type 2 mucosal immune model and a murine model for HDM-induced acute allergic asthma.

To the best of our knowledge, this is the first study on the development and use of an *in vitro* bronchial epithelial mucosal immune model using HDM as the allergenic trigger. This model is based on a previously model for the intestine (31–33). It is known that epithelial cells play a key role in initiating the allergic sensitization

process by influencing the maturation and activation of DCs (34). Therefore, Calu-3 cells were used as model for BEC. Although traditional transwell culture methods are fully submerged (35, 36), ciliated characteristics of the bronchial epithelium are diminished, resulting in less relevant physiological conditions. Furthermore, Calu-3 cells are known to produce mucus which is a relevant feature in airway barrier function (37). ALI culture is suggested to reflect a more representative condition as the cells are exposed to medium via the basolateral compartment and air via the apical compartment resembling the physiological airway conditions (38, 39). Even though the TEER development of ALI cultured BEC was significantly lower compared to submerged cultured BEC, the ALI cultured BEC still acquired a high degree of barrier resistance and therefore this culture method was selected for the succeeding experiments.

It is known that HDM can disrupt bronchial epithelium integrity via proteolytic breakdown of tight junction proteins (38, 40–42). In the current study, we observed that the TEER was significantly decreased already at a relatively low apical HDM exposure (10 μ g/ml) within 1 h after exposure. Exposure to the lowest HDM dose was also sufficient to enhance release of alarmins, known to drive a subsequent type 2 response via DCs. Next, the immunological crosstalk between BEC and DC was studied during HDM exposure and compared to HDM exposure of DC alone, in addition to the subsequent functional T cell response after coculture with HDM-DC or HDM-BEC-DC was investigated. In the absence of BEC, HDM exposed DC showed increased IL33 and TGF β secretion together with enhanced CD86 expression, while IL8 secretion was reduced. IL33 is a type 2 instructing epithelial derived alarmin, which can be produced by DCs when stimulated via Dectin-1. From murine experiments, it is known that HDM binding to Dectin-1 is crucial for DC migration, Th2 development and allergic airway inflammation (43). Although IL33 is mainly known for its proinflammatory, type 2 driving




FIGURE 5

T cell responses in lung tissue. Lung tissue of sacrificed mice was collected to determine the population of (A) activated T helper 2 cells based on the expression of T1ST2 and CD69 and the concentration of (B) IL13 in lung tissue as well as the population of (C) activated T helper 1 cells based on the expression of CXCR3 and CD69 and the concentration of (D) IFN γ in lung tissue. (E) Representative flow cytometry samples from Sham and HDM mice. When data fit a normal distribution and had an equal variability of differences, Sham and HDM groups are analyzed by unpaired t-test, the intervention groups were compared to the HDM group by One-Way ANOVA followed by a Dunnett's multiple comparisons test. When these criteria were not met, data was transformed, a Mann-Whitney test or Kruskal-Wallis test with Dunn's multiple comparisons test was performed, $n = 6-12$, mean \pm SEM (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$).

properties, this cytokine can induce the development of Treg cells as well (44). Furthermore, increased expression of CD86 by DCs has been linked to promote the development of an allergic type 2 response (45, 46). Yet in the presence of regulatory TGF β this enhanced CD86 expression was linked to a tolerogenic phenotype in which IL8 secretion was decreased as well (47). This may imply that HDM exposure to DC may instruct a more regulatory phenotype. However, subsequent coculture of HDM-DCs with naïve Th cells had no significant effect on Treg cell development nor regulatory cytokine secretion (IL10). Yet the developed T cells did show lower intracellular expression of both IL13 as well as IFN γ , indicating some immunosuppressive effects which may relate to the phenotypic changes of HDM-DC. Previously, it was demonstrated that exposing DCs from healthy donors to HDM did not result in subsequent activation of naïve Th cells, while DCs from allergic patients promoted Th2 cell polarization upon HDM exposure (48). These differences in DC responses to HDM between allergic and healthy individuals may explain the observations in this study and highlights the relevance to further investigate the role of DCs in allergic diseases.

However, when BEC were exposed to HDM while cocultured with DC, secretion of TSLP and expression of CD80 on DC was enhanced, while TGF β concentrations decreased. Although CD80 has been linked to a type 1 and Treg cell instruction (45), we hypothesize that due to the increase in TSLP and decrease in TGF β the functional outcome of DC development was altered, leading to DCs that directed the consecutive T cell response towards a type 2 prone cytokine pattern. HDM-BEC-DC instructed T cells to increase the release of IL4, and the ratio of IL4 over IFN γ cytokine secretion, while a lower percentage of Th cells contained intracellular IFN γ when compared to medium controls. Epithelial-derived TSLP promotes DCs to induce Th2 differentiation resulting in IL4 secretion (49–51). In addition, TGF β stimulates the development of tolerogenic responses while inhibiting the production of proinflammatory cytokines (52). Hence, the increased secretion of TSLP and reduced TGF β secretion seemed sufficient to develop a type 2 directed DC response, affecting the subsequent coculture with naïve Th cells, as generally observed in asthma allergic patients. These results emphasize the relevance of further studying the crosstalk between BEC and DCs in shaping the mucosal immune response to aeroallergens.

After the observation that HDM only induced a type 2 driven immune response in presence of BEC, the immunomodulatory effect of 2'FL and 3FL were investigated in the presence of BEC, thus using the BEC-DC-T model. Prior to HDM exposure, cocultured BEC and moDC were preincubated with a low dose of these HMOS in the basolateral compartment, mimicking the physiological concentrations that can become systemically available via the bloodstream after ingestion of HMOS in infants (24–26). Both 2'FL as well as 3FL prevented the HDM-induced release of TSLP and IL8. IL8 secretion from DC can be triggered in the presence of TSLP (53), justifying the similar secretion patterns observed in these cytokines. However, in this setting IL8 may also have been derived from BEC. The general decrease in HDM induced TSLP and IL8 secretion from BEC-DC after HMOS preincubation was associated with a reduction in HDM increased IL4 over IFN γ secretion by the T cells which were cocultured with the BEC-DC. Hence both HMOS not only suppressed HDM induced type 2 activation in BEC-DC cultures, it also prevented the instruction of type 2 prone cytokine secretion by T cells exposed to DC from these cultures. These data suggest that the HMOS are able to prevent HDM-induced TSLP secretion and hereby may be able to modify DC function to steer the subsequent T cell response away from a type 2 reaction, which is provoked by HDM when

exposed to BEC (54, 55). Although here BEC-DC cocultures were incubated 24 h with HMOS, another physiological relevant approach for future studies would be to prime the moDCs with these low doses of HMOS already during their differentiation from monocyte into DC.

HMOS naturally occur at a 1–2.5% concentration in human milk. 2'FL and 3FL are generally the dominant HMOS present in human milk. *In vitro* we studied the dose of 0.01 and 0.05%, since it is estimated that 1–2% of the HMOS in milk could become available systemically (56). Interestingly, only 0.01% 3FL preincubation restored the HDM-induced decrease of TGF β secretion during BEC-DC coculture. During subsequent coculture of BEC-DC with T cells, 0.01% 3FL preincubation also significantly reduced HDM-BEC-DC instructed IL4 secretion by T cells, while preventing the decrease in percentage of IFN γ expressing cells as observed in the HDM-BEC-DC/T condition. TGF β is known for its regulatory functions, such as promoting the development of Treg while suppressing Th1 and Th2 responses (57). Here, 0.01% 3FL preincubation mediated enhanced secretion of TGF β in BEC-DCs resulting in restoration of the HDM-induced type 1 and type 2 response in T cells, while Treg differentiation remained unaffected. Previously, we demonstrated that both 2'FL and 3FL preincubation of intestinal epithelial cells prior to ovalbumin exposure directed moDC to induce enhanced release of IL10 by T cells in an *in vitro* intestinal mucosal immune model for ovalbumin-induced type 2 inflammation (58). Hence, both 2'FL and 3FL may be able to directly affect epithelial cells and/or immune cells and in this way suppress type 2 activation, while permitting regulatory cytokine secretion. In general not much information is available on systemic HMOS concentrations, future dose-finding studies are warranted also including lower concentrations (24). In addition, future studies should aim to combine different HMOS based on their relative presence in human milk (59) to study the optimal composition for immune support.

To further study the potential immunomodulatory effects of 2'FL and 3FL, a murine model for HDM-induced acute allergic asthma was used. Mice received a control, 2'FL or 3FL containing diet 2 weeks prior to and during HDM sensitization and challenge. Previously, this murine model was used to study other prebiotic dietary interventions (60, 61). It was demonstrated that diets containing 1% w/w galacto-oligosaccharides prevent the influx of inflammatory cells into the lungs in HDM sensitized and challenged mice (60, 62), which was also demonstrated for a high-pectin fiber diet (63). In the current study, HDM sensitized and challenged mice did not show signs of increased airway hyperresponsiveness (Supplementary Figure 4A). The influx of inflammatory cells was significantly increased in HDM-allergic mice, yet dietary intervention with 2'FL or 3FL did not decrease the influx of cells into the lungs significantly. However, the mice receiving 1% 2'FL or 0.5% 3FL containing diets had lower HDM-specific IgE levels in serum, indicative of reduced allergic sensitization towards HDM. Although this did not significantly protect against airway eosinophilia, a declining pattern was observed in the mice fed 3FL. This may associate with the reduced levels of HDM-IgE in this group, since HDM-IgE and the number of eosinophils were positively correlated. The same may apply for the macrophages, however here the correlation with HDM-IgE was less clear. Changes in dietary fiber or prebiotics intake indeed can affect allergy related humoral responses, as was previously demonstrated in HDM sensitized mice receiving a low-fiber diet that had higher levels of total IgE in serum, compared to HDM sensitized mice fed a high-fiber diet (63).

The 2'FL or 3FL containing diets did not affect the tendency of HDM to induce activation of Th1 and Th2 cells. Nonetheless, mice receiving the

1% 3FL containing diet had lower levels of both IL13 and IFN γ present in lung tissue, suggesting an additional anti-inflammatory capacity of 3FL compared to 2'FL which was also observed in the *in vitro* studies. Reduced cytokine levels were also observed in lung homogenates of HDM sensitized and challenged mice being fed GOS/lcFOS or scFOS/lcFOS plus *Bifidobacterium breve* M16V supplemented diets compared to control diet (64). Of note: the HMOS used in the *in vitro* studies were enzymatically derived from lactose. However, due to limitations in production capacity, the HMOS used in the *in vivo* studies were produced in genetically modified *E. coli*. Previously, we demonstrated that the source of HMOS (bacterial or enzymatic produced) affects the immunomodulatory effects in different types of *in vitro* immunoassays (65). Future studies should take into account the possible translational difference between lactose derived versus *E. coli* derived HMOS on immunomodulatory efficacy. Even though single 2'FL or 3FL did not protect against HDM induced eosinophilic airway inflammation, the *in vivo* results do indicate 2'FL or 3FL to protect against HDM allergic sensitization as was predicted by the *in vitro* model.

Our current knowledge of the mechanisms underlying HMOS mediated immunomodulation are poorly understood. However, several potential routes have been described, including both direct and indirect immunomodulatory effect, via which HMOS may prevent allergic sensitization (65). Future studies should focus on exploring the underlying mechanisms via which HMOS exert their immunomodulatory effect. This will contribute to understanding structure–function relationships of HMOS and their role in immunomodulation as relevant in early life immune development.

5 Conclusion

In this study, we established an *in vitro* coculture model for HDM induced type 2 BEC-DC activation and subsequent development of a type 2 Th cell response, which resembles the *in vivo* situation. BEC necessary *in vitro* to induce type 2 immunity after HDM exposure via modulation of DC functionality. Preincubation of BEC-DC with 2'FL and 3FL largely prevented HDM-induced BEC-DC activation and suppressed downstream type 2 over type 1 T cell activation. Although both 2'FL and 3FL reduced HDM-specific IgE in a murine model for HDM allergic asthma, these mice were not protected against airway inflammation. Future studies should consider improvement of *in vitro* models from a 3R perspective to further investigate the potential allergy preventive effects of early life influencing factors.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The human samples used in this study were acquired from blood was collected from healthy donor volunteers at the Dutch Blood Bank. Written informed consent to participate in this study was not required from the participants or the participants' legal guardians/next of kin in accordance with the national legislation and the institutional requirements. The

animal study was approved by Animal Welfare Body Utrecht under an ethical license provided by the Centrale Commissie Dierproeven. The study was conducted in accordance with the local legislation and institutional requirements.

Author contributions

MZ: Writing – original draft, Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Visualization. JK: Data curation, Writing – review & editing. AB: Data curation, Writing – review & editing. MK: Data curation, Writing – review & editing. IA: Data curation, Methodology, Writing – review & editing. TL-M: Data curation, Methodology, Writing – review & editing. NK: Data curation, Methodology, Writing – review & editing. GF: Supervision, Writing – review & editing. JG: Supervision, Writing – review & editing. BvL: Conceptualization, Supervision, Funding acquisition, Writing – review & editing. LW: Conceptualization, Formal analysis, Supervision, Funding acquisition, Writing – review & editing.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research was funded by the PPP allowance made available by TKI Health Holland, Top Sector Life Sciences and Health, to the Utrecht University to stimulate public-private partnerships (LSHM1037, acronym HMOS4ALL).

Conflict of interest

JG and BvL are partially employed by Danone Nutricia Research B.V.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fnut.2025.1491430/full#supplementary-material>

References

- Lambrecht BN, Hammad H. The immunology of asthma. *Nat Immunol.* (2015) 16:45–56. doi: 10.1038/ni.3049
- Akar-Ghbiril N, Casale T, Custovic A, Phipatanakul W. Allergic endotypes and phenotypes of asthma. *J Allergy Clin Immunol Pract.* (2020) 8:429–40. doi: 10.1016/j.jaip.2019.11.008
- Burbank AJ, Sood AK, Kesic MJ, Peden DB, Hernandez ML. Environmental determinants of allergy and asthma in early life. *J Allergy Clin Immunol.* (2017) 140:1–12. doi: 10.1016/j.jaci.2017.05.010
- Yang L, Fu J, Zhou Y. Research Progress in atopic march. *Front Immunol.* (2020) 11:1907. doi: 10.3389/fimmu.2020.01907
- Mims JW. Asthma: definitions and pathophysiology. *Int Forum Allergy Rhinol.* (2015) 5:S2–6. doi: 10.1002/alf.21609
- Yu LCH. Intestinal epithelial barrier dysfunction in food hypersensitivity. *J Allergy (Cairo).* (2012) 2012:1–11. doi: 10.1155/2012/596081
- Hellings PW, Steelant B. Epithelial barriers in allergy and asthma. *J Allergy Clin Immunol.* (2020) 145:1499–509. doi: 10.1016/j.jaci.2020.04.010
- Mattila P, Joenväärä S, Renkonen J, Toppila-Salmi S, Renkonen R. Allergy as an epithelial barrier disease. *Clin Transl Allergy.* (2011) 1:5. doi: 10.1186/2045-7022-1-5
- Wan H, Winton HL, Soeller C, Tovey ER, Gruenert DC, Thompson PJ, et al. Der p 1 facilitates transepithelial allergen delivery by disruption of tight junctions. *J Clin Invest.* (1999) 104:123–33. doi: 10.1172/JCI5844
- Reddy VB, Lerner EA. Activation of mas-related G-protein-coupled receptors by the house dust mite cysteine protease Der p 1 provides a new mechanism linking allergy and inflammation. *J Biol Chem.* (2017) 292:17399–406. doi: 10.1074/jbc.M117.787887
- Lambrecht BN, Hammad H. Dendritic cell and epithelial cell interactions at the origin of murine asthma. *Ann Am Thorac Soc.* (2014) 11:S236–43. doi: 10.1513/AnnalsATS.201405-218AW
- Morianos I, Semitekolou M. Dendritic cells: critical regulators of allergic asthma. *Int J Mol Sci.* (2020) 21:7930. doi: 10.3390/ijms21217930
- Murphy K, Weaver C, Weaver M, Geha R, Notarangelo L. (2017). Janeway's immunobiology.
- Zuurveld M, van Witenburg NP, Garssen J, Folkerts G, Stahl B, van't Land B, et al. Immunomodulation by human milk oligosaccharides: the potential role in prevention of allergic diseases. *Front Immunol.* (2020) 11:801. doi: 10.3389/fimmu.2020.00801
- da Silva EZM, Jamur MC, Oliver C. Mast cell function: a new vision of an old cell. *J Histochem Cytochem.* (2014) 62:698–738. doi: 10.1369/0022155414545334
- Victora CG, Bahl R, Barros AJD, França GVA, Horton S, Krasevec J, et al. Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect. *Lancet.* (2016) 387:475–90. doi: 10.1016/S0140-6736(15)01024-7
- Klopp A, Vehling L, Becker AB, Subbarao P, Mandhane PJ, Turvey SE, et al. Modes of infant feeding and the risk of childhood asthma: a prospective birth cohort study. *J Pediatr.* (2017) 190:192–199.e2. doi: 10.1016/j.jpeds.2017.07.012
- Mosca F, Gianni ML. Human milk: composition and health benefits. *Med Surg Pediatr.* (2017) 39:155. doi: 10.4081/pmc.2017.155
- Thurl S, Munzert M, Boehm G, Matthews C, Stahl B. Systematic review of the concentrations of oligosaccharides in human milk. *Nutr Rev.* (2017) 75:920–33. doi: 10.1093/nutrit/nux044
- Lyons KE, Ryan CA, Dempsey EM, Ross RP, Stanton C. Breast milk, a source of beneficial microbes and associated benefits for infant health. *Nutrients.* (2020) 12:1039. doi: 10.3390/nu12041039
- Ayechu-Muruzabal V, van Stigt AH, Mank M, Willemsen LEM, Stahl B, Garssen J, et al. Diversity of human Milk oligosaccharides and effects on early life immune development. *Front Pediatr.* (2018) 6:6. doi: 10.3389/fped.2018.00239
- Folkerts J, Stadhouders R, Redegeld FA, Tam SY, Hendriks RW, Galli SJ, et al. Effect of dietary Fiber and metabolites on mast cell activation and mast cell-associated diseases. *Front Immunol.* (2018) 9:1067. doi: 10.3389/fimmu.2018.01067
- Eriksen KG, Christensen SH, Lind MV, Michaelsen KF. Human milk composition and infant growth. *Curr Opin Clin Nutr Metabol Care.* (2018) 21:200–6. doi: 10.1097/MCO.0000000000000466
- Goehring KC, Kennedy AD, Prieto PA, Buck RH. Direct evidence for the presence of human milk oligosaccharides in the circulation of breastfed infants. *PLoS One.* (2014) 9:1–11. doi: 10.1371/journal.pone.0101692
- Rudloff S, Pohlentz G, Diekmann L, Egge H, Kunz C. Urinary excretion of lactose and oligosaccharides in preterm infants fed human milk or infant formula. *Acta Paediatr Int J Paediatr.* (1996) 85:598–603. doi: 10.1111/j.1651-2227.1996.tb14095.x
- Ruhaak LR, Stroble C, Underwood MA, Lebrilla CB. Detection of milk oligosaccharides in plasma of infants. *Anal Bioanal Chem.* (2014) 406:5775–84. doi: 10.1007/s00216-014-8025-z
- Boehm G, Stahl B. Oligosaccharides from Milk. *J Nutr.* (2007) 137:847S–9S. doi: 10.1093/jn/137.3.847S
- Ramani S, Stewart CJ, Laucirica DR, Ajami NJ, Robertson B, Autran CA, et al. Human milk oligosaccharides, milk microbiome and infant gut microbiome modulate neonatal rotavirus infection. *Nat Commun.* (2018) 9:1–12. doi: 10.1038/s41467-018-07476-4
- Vandenplas Y, Berger B, Carnielli VP, Ksiazyk J, Lagström H, Luna MS, et al. Human Milk oligosaccharides: 2'-Fucosyllactose (2'-FL) and lacto-N-Neotetraose (LNnT) in infant formula. *Nutrients.* (2018) 10:1161. doi: 10.3390/nu10091161
- Reverri EJ, Devitt AA, Kajzer JA, Baggs GE, Borschel MW. Review of the clinical experiences of feeding infants formula containing the human milk oligosaccharide 2'-Fucosyllactose. *Nutrients.* (2018) 10:1346. doi: 10.3390/nu10101346
- Bueno-Díaz C, Zuurveld M, Ayechu-Muruzabal V, Korsten SGPJ, Martín-Pedraza L, Parrón-Ballesteros J, et al. Mustard seed major allergen sin a1 activates intestinal epithelial cells and also dendritic cells that drive type 2 immune responses. *Food Funct.* (2024) 15:6488–501. doi: 10.1039/D4FO01980F
- Zuurveld M, Ogrodowczyk AM, Benedé S, Czolk R, Lucia Bavaro S, Randow S, et al. Allergenic shrimp tropomyosin distinguishes from a non-allergenic chicken homolog by pronounced intestinal barrier disruption and downstream Th2 responses in epithelial and dendritic cell (co)culture. *Nutrients.* (2024) 16:1192. doi: 10.3390/nu16081192
- Zuurveld M, Bueno Díaz C, Redegeld F, Folkerts G, Garssen J, van't Land B, et al. An advanced in vitro human mucosal immune model to predict food sensitizing allergenicity risk: a proof of concept using ovalbumin as model allergen. *Front Immunol.* (2023) 13:1073034. doi: 10.3389/fimmu.2022.1073034
- Hammad H, Lambrecht BN. Dendritic cells and epithelial cells: linking innate and adaptive immunity in asthma. *Nat Rev Immunol.* (2008) 8:193–204. doi: 10.1038/nri2275
- Huang YC, Leyko B, Frieri M. Effects of omalizumab and budesonide on markers of inflammation in human bronchial epithelial cells. *Ann Allergy Asthma Immunol.* (2005) 95:443–51. doi: 10.1016/S1081-1206(10)61170-2
- Aydin M, Naumova EA, Paulsen F, Zhang W, Goepferich F, Theis C, et al. House dust mite exposure causes increased susceptibility of nasal epithelial cells to adenovirus infection. *Viruses.* (2020) 12:1151. doi: 10.3390/v12101151
- Wu X, Zhang G, Du X. Cigarette smoke extract induces MUC5AC expression through the ROS/IP3R/Ca²⁺ pathway in Calu-3 cells. *Int J COPD.* (2024) 19:1635–47. doi: 10.2147/COPD.S469866
- López-Rodríguez JC, Rodríguez-Coira J, Benedé S, Barbas C, Barber D, Villalba MT, et al. Comparative metabolomics analysis of bronchial epithelium during barrier establishment after allergen exposure. *Clin Transl Allergy.* (2021) 11:e12051. doi: 10.1002/ct2.12051
- Kreft ME, Jerman UD, Lasič E, Hevir-Kene N, Rižner TL, Peternel L, et al. The characterization of the human cell line Calu-3 under different culture conditions and its use as an optimized in vitro model to investigate bronchial epithelial function. *Eur J Pharm Sci.* (2015) 69:1–9. doi: 10.1016/j.ejps.2014.12.017
- Hming D, Le Yqing WY, Hjin Z, Cwen H, Yhui H, et al. Extracellular heat shock protein 90 α mediates HDM-induced bronchial epithelial barrier dysfunction by activating rho a/MLC signaling. *Respir Res.* (2017) 18:111. doi: 10.1186/s12931-017-0593-y
- Ogi K, Ramezanzpour M, Liu S, Ferdoush Tuli J, Bennett C, Suzuki M, et al. Der p 1 disrupts the epithelial barrier and induces IL-6 production in patients with house dust mite allergic rhinitis. *Front Allergy.* (2021) 2:37. doi: 10.3389/falgy.2021.692049
- Post S, Nawijn MC, Jonker MR, Kliphuis N, van den Berge M, van Oosterhout AJ, et al. (2013). House dust mite-induced calcium signaling instigates epithelial barrier dysfunction and CCL20 production.
- Ito T, Hirose K, Norimoto A, Tamachi T, Yokota M, Saku A, et al. Dectin-1 plays an important role in house dust mite-induced allergic airway inflammation through the activation of CD11b+ dendritic cells. *J Immunol.* (2017) 198:61–70. doi: 10.4049/jimmunol.1502393
- Matta BM, Lott JM, Mathews LR, Liu Q, Rosborough BR, Blazar BR, et al. IL33 is an unconventional alarmin that stimulates IL2 secretion by dendritic cells to selectively expand IL33R/ST2+ regulatory T cells. *J Immunol.* (2014) 193:4010–20. doi: 10.4049/jimmunol.1400481
- Kuchroo VK, Prabhu Das M, Brown JA, Ranger AM, Zamvil SS, Sobel RA, et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. *Cell.* (1995) 80:707–18. doi: 10.1016/0092-8674(95)90349-6
- Wijk F, Nierkens S, de Jong W, Wehrens EJM, Boon L, van Kooten P, et al. The CD28/CTLA-4-B7 signaling pathway is involved in both allergic sensitization and tolerance induction to orally administered Peanut proteins. *J Immunol.* (2007) 178:6894–900. doi: 10.4049/jimmunol.178.11.6894
- Perdijk O, Joost Van Neerven RJ, Meijer B, Savelkoul HFJ, Brugman S. Induction of human tolerogenic dendritic cells by 3'-sialyllactose via TLR4 is explained by LPS contamination. *Glycobiology.* (2018) 28:126–30. doi: 10.1093/glycob/cwx106
- Charbonnier AS, Hammad H, Gosset P, Stewart GA, Alkan S, Tonnel AB, et al. Der p 1-pulsed myeloid and plasmacytoid dendritic cells from house dust mite-sensitized allergic patients dysregulate the T cell response. *J Leukoc Biol.* (2003) 73:91–9. doi: 10.1189/jlb.0602289

49. Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, et al. Human epithelial cells trigger dendritic cell-mediated allergic inflammation by producing TSLP. *Nat Immunol.* (2002) 3:673–80. doi: 10.1038/ni805
50. Pattarini L, Trichot C, Bogiatzi S, Grandclaudon M, Meller S, Keuylian Z, et al. TSLP-activated dendritic cells induce human T follicular helper cell differentiation through OX40-ligand. *J Exp Med.* (2017) 214:1529–46. doi: 10.1084/jem.20150402
51. Gilliet M, Soumelis V, Watanabe N, Hanabuchi S, Antonenko S, De Waal-Malefyt R, et al. Human dendritic cells activated by TSLP and CD40L induce proallergic cytotoxic T cells. *J Exp Med.* (2003) 197:1059–63. doi: 10.1084/jem.20030240
52. Bode L. The functional biology of human milk oligosaccharides. *Early Hum Dev.* (2015) 91:619–22. Available from: doi: 10.1016/j.earlhumdev.2015.09.001
53. Rivas MN, Chatila TA. Regulatory T cells in allergic diseases. *J Allergy Clin Immunol.* (2017) 138:639–52.
54. Ito T, Yhsi W, Duramad O, Hori T, Delespesse GJ, Watanabe N, et al. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. *J Exp Med.* (2005) 202:1213–23. doi: 10.1084/jem.20051135
55. Soyylmaz B, Mikš MH, Röhrig CH, Matwiejuk M, Meszaros-matwiejuk A, Vignæs LK. The mean of milk: a review of human milk oligosaccharide concentrations throughout lactation. *Nutrients.* (2021) 13:1–22. doi: 10.3390/nu13082737
56. Hammad H, Chieppa M, Perros F, Willart MA, Germain RN, Lambrecht BN. House dust mite allergen induces asthma via TLR4 triggering of airway structural cells. *Nat Med.* (2009) 15:410–6. doi: 10.1038/nm.1946
57. Scheurer S, Toda M, Vieths S. What makes an allergen? *Clin Exp Allergy.* (2015) 45:1150–61. doi: 10.1111/cea.12571
58. Saito A, Horie M, Nagase T. TGF- β signaling in lung health and disease. *Int J Mol Sci.* (2018) 19:1–18. doi: 10.3390/ijms19082460
59. Zuurveld M, Kiliaan PCJ, van Grinsven SEL, Folkerts G, Garssen J, van't Land B, et al. Ovalbumin induced epithelial activation directs mo DC to instruct type 2 inflammation in T cells which is differentially modulated by 2'-fucosyllactose and 3-fucosyllactose. *J Innate Immun.* (2022) 15:222–39. doi: 10.1159/000526528
60. Verheijden KAT, Willemsen LEM, Braber S, Leusink-Muis T, Delsing DJM, Garssen J, et al. Dietary galacto-oligosaccharides prevent airway eosinophilia and hyperresponsiveness in a murine house dust mite-induced asthma model. *Respir Res.* (2015) 16:1–9. doi: 10.1186/s12931-015-0171-0
61. Verheijden KAT, Braber S, Leusink-Muis T, Jeurink PV, Thijssen S, Kraneveld AD, et al. The combination therapy of dietary galacto-oligosaccharides with budesonide reduces pulmonary Th2 driving mediators and mast cell degranulation in a murine model of house dust mite induced asthma. *Front Immunol.* (2018) 9:1–12. doi: 10.3389/fimmu.2018.02419
62. Yasuda A, Inoue KI, Sanbongi C, Yanagisawa R, Ichinose T, Yoshikawa T, et al. Dietary supplementation with fructooligosaccharides attenuates airway inflammation related to house dust mite allergen in mice. *Int J Immunopathol Pharmacol.* (2010) 23:727–35. doi: 10.1177/039463201002300306
63. Trompette A, Gollwitzer ES, Yadava K, Sichelstiel AK, Sprenger N, Ngom-Bru C, et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. *Nat Med.* (2014) 20:159–66. doi: 10.1038/nm.3444
64. Verheijden KAT, Willemsen LEM, Braber S, Leusink-Muis T, Jeurink PV, Garssen J, et al. The development of allergic inflammation in a murine house dust mite asthma model is suppressed by synbiotic mixtures of non-digestible oligosaccharides and *Bifidobacterium breve* M-16V. *Eur J Nutr.* (2016) 55:1141–51. doi: 10.1007/s00394-015-0928-8
65. Zuurveld M, Ayechu-Muruzabal V, Folkerts G, Garssen J, Van LB, Willemsen LEM. Specific human Milk oligosaccharides differentially promote Th1 and regulatory responses in a CpG-activated epithelial/immune cell Coculture. *Biomol Ther.* (2023) 13:1–18. doi: 10.3390/biom13020263